TY - JOUR
T1 - 12/15-lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function
AU - Rothe, Tobias
AU - Gruber, Florian
AU - Uderhardt, Stefan
AU - Ipseiz, Natacha
AU - Rössner, Susanne
AU - Oskolkova, Olga
AU - Blüml, Stephan
AU - Leitinger, Norbert
AU - Bicker, Wolfgang
AU - Bochkov, Valery N.
AU - Yamamoto, Masayuki
AU - Steinkasserer, Alexander
AU - Schett, Georg
AU - Zinser, Elisabeth
AU - Krönke, Gerhard
N1 - Publisher Copyright:
© 2015, American Society for Clinical Investigation. All rights reserved.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - DCs are able to undergo rapid maturation, which subsequently allows them to initiate and orchestrate T cell-driven immune responses. DC maturation must be tightly controlled in order to avoid random T cell activation and development of autoimmunity. Here, we determined that 12/15-lipoxygenase-meditated (12/15-LO-mediated) enzymatic lipid oxidation regulates DC activation and fine-tunes consecutive T cell responses. Specifically, 12/15-LO activity determined the DC activation threshold via generation of phospholipid oxidation products that induced an antioxidative response dependent on the transcription factor NRF2. Deletion of the 12/15-LO-encoding gene or pharmacologic inhibition of 12/15-LO in murine or human DCs accelerated maturation and shifted the cytokine profile, thereby favoring the differentiation of Th17 cells. Exposure of 12/15-LO-deficient DCs to 12/15-LO-derived oxidized phospholipids attenuated both DC activation and the development of Th17 cells. Analysis of lymphatic tissues from 12/15-LO-deficient mice confirmed enhanced maturation of DCs as well as an increased differentiation of Th17 cells. Moreover, experimental autoimmune encephalomyelitis in mice lacking 12/15-LO resulted in an exacerbated Th17-driven autoimmune disease. Together, our data reveal that 12/15-LO controls maturation of DCs and implicate enzymatic lipid oxidation in shaping the adaptive immune response.
AB - DCs are able to undergo rapid maturation, which subsequently allows them to initiate and orchestrate T cell-driven immune responses. DC maturation must be tightly controlled in order to avoid random T cell activation and development of autoimmunity. Here, we determined that 12/15-lipoxygenase-meditated (12/15-LO-mediated) enzymatic lipid oxidation regulates DC activation and fine-tunes consecutive T cell responses. Specifically, 12/15-LO activity determined the DC activation threshold via generation of phospholipid oxidation products that induced an antioxidative response dependent on the transcription factor NRF2. Deletion of the 12/15-LO-encoding gene or pharmacologic inhibition of 12/15-LO in murine or human DCs accelerated maturation and shifted the cytokine profile, thereby favoring the differentiation of Th17 cells. Exposure of 12/15-LO-deficient DCs to 12/15-LO-derived oxidized phospholipids attenuated both DC activation and the development of Th17 cells. Analysis of lymphatic tissues from 12/15-LO-deficient mice confirmed enhanced maturation of DCs as well as an increased differentiation of Th17 cells. Moreover, experimental autoimmune encephalomyelitis in mice lacking 12/15-LO resulted in an exacerbated Th17-driven autoimmune disease. Together, our data reveal that 12/15-LO controls maturation of DCs and implicate enzymatic lipid oxidation in shaping the adaptive immune response.
UR - http://www.scopus.com/inward/record.url?scp=84929000116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929000116&partnerID=8YFLogxK
U2 - 10.1172/JCI78490
DO - 10.1172/JCI78490
M3 - Article
C2 - 25844901
AN - SCOPUS:84929000116
SN - 0021-9738
VL - 125
SP - 1944
EP - 1954
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 5
ER -